Friday, August 15 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Friday, August 15 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Thursday, August 14 8:30–9:30am
Brain Check: Promoting Brain Health and Detecting Cognitive Impairment
Friday, August 15 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Friday, August 15 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Friday, August 15 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Friday, August 15 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Friday, August 15 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Friday, August 15 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Thursday, August 14 4:30–6pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Thursday, August 14 8:30–9:30am
Brain Check: Promoting Brain Health and Detecting Cognitive Impairment
Thursday, August 14 7:30–8:30am
Thursday, August 14 4:30–6pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Thursday, August 14 1:30–2:30pm
Brain Aneurysms Are Treatable: But They Must Be Diagnosed First
Friday, August 15 1:30–2:30pm
Cardiology in Focus: Breaking Down the Latest Guideline Updates
Financial Disclosures
- Charles E. Argoff, MD, FABPM
- AbbVie, Researcher; AbbVie, Lilly, Scilex, Lundbeck, Averitas Pharma, Teva, Impel, Kowa Pharmaceuticals, Nevro, Speaker; Collegium, Scilex, Vertex, Xgene Pharma, Tris, PainScripts, Nevro, Consultant; Lundbeck and Teva, Other; Pfizer and Trevana, Stock Holder (publicly traded company)
- Amy Clouse, MD, FAAFP
- Astellas Pharmacueticals, Speaker; Eli Lilly; Novo Nordisk, Stock Holder (publicly traded company)
- Oscar A. de Leon-Casasola, MD
- Merck Pharmaceuticals, Vertex Pharmaceuticals., Consultant
- Katherine E. Galluzzi, DO, CMD, FACOFP
- No relevant financial relationships disclosed.
- Aubrey J. Grant, MD, FACC
- No relevant financial relationships disclosed.
- Jacob H. Johnson, MD
- No relevant financial relationships disclosed
- Pamela Kushner, MD, FAAFP
- GlaxoSmithKline, Novo Nordisk, AstraZeneca, Lilly, Abbott, Haleon, Bausch/SALIX, Corcept, Boehringer Ingelheim, Advisor; Novo Nordisk, Lilly, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, Abbott, Phathom, Bausch/SALIX, Intuity, Pfizer, and Janssen., Speaker
- Joynita R. Nicholson, DO, DABOM, FOMA
- No relevant financial relationships disclosed.
- Pierre N. Tariot, MD
- Information to come
- Charles Vega, MD, FAAFP
- Boehringer Ingelheim, and Exact Sciences, Consultant
- Shirah Vollmer, MD
- No relevant financial relationships disclosed
- Karol E. Watson, MD, PhD
- Amarin, Consultant; Amgen, Consultant; Boehringer Ingelheim, Consultant; Eli Lilly, Consultant; Novartis, Consultant
Other Disclosures
Pamela Kushner, MD, FAAFP (Moderator, Reviewer): Speaker and Advisor for AstraZeneca, Boehringer Ingelheim, Corcept, GSK, Haleon, and Novo Nordisk; Speaker for Astellas, Bayer, Janssen, Lilly, and Phathom; Advisor for Abbott and Bausch/SALIX
All other non-faculty contributors involved in the moderating, planning, development, editing and review of the content have disclosed no relevant financial relationships.